Tirzepatide for Diabetes: What the Evidence Shows
What human and animal studies show about Tirzepatide for diabetes, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 843
- PubMed records, our ledger
- Animal studies
- 48
- PubMed records, our ledger
- Studies we summarised
- 8
- with an outcome for diabetes
Evidence for diabetes
Each row is an outcome related to diabetes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Cardiovascular death, MI or stroke | Primary events occurred in 12.2% (tirzepatide) vs 13.1% (dulaglutide); hazard ratio 0.92 (95.3% CI 0.83 to 1.01), noninferior but superiority not shown (P = 0.09). | Human RCTn = 13165 | The New England journal of medicine 2025, PMID 41406444 |
| Body weight change | Mean bodyweight change at week 72 was -12·8% (10 mg) and -14·7% (15 mg) versus -3·2% with placebo in people with type 2 diabetes. | Human RCTn = 938 | Lancet 2023, PMID 37385275 |
| HbA1c change | Glycated hemoglobin fell by 2.40% (10 mg) and 2.34% (15 mg) versus 0.86% with placebo at week 40. | Human RCTn = 475 | JAMA 2022, PMID 35133415 |
| Body weight | Body weight changed by -5.4, -7.5 and -8.8 kg with tirzepatide 5, 10 and 15 mg versus 1.6 kg with placebo. | Human RCTn = 475 | JAMA 2022, PMID 35133415 |
| HbA1c change | Mean glycated hemoglobin fell by 1·87% (5 mg), 1·89% (10 mg) and 2·07% (15 mg) versus +0·04% with placebo. | Human RCTn = 478 | Lancet 2021, PMID 34186022 |
| Body weight | Tirzepatide caused a dose-dependent weight loss of 7·0 to 9·5 kg. | Human RCTn = 478 | Lancet 2021, PMID 34186022 |
| HbA1c change vs semaglutide | Glycated hemoglobin fell by 2.01, 2.24 and 2.30 percentage points with tirzepatide 5, 10 and 15 mg versus 1.86 with semaglutide. | Human controlled trialn = 1879 | The New England journal of medicine 2021, PMID 34170647 |
| HbA1c change vs insulin degludec | Glycated hemoglobin fell by 1·93%, 2·20% and 2·37% with tirzepatide 5, 10 and 15 mg versus 1·34% with insulin degludec at week 52. | Human RCTn = 1437 | Lancet 2021, PMID 34370970 |
| Body weight vs insulin degludec | Tirzepatide lowered bodyweight by 7·5 to 12·9 kg while insulin degludec increased it by 2·3 kg. | Human RCTn = 1437 | Lancet 2021, PMID 34370970 |
| HbA1c change vs glargine | Glycated hemoglobin fell by 2·43% (10 mg) and 2·58% (15 mg) with tirzepatide versus 1·44% with glargine at 52 weeks. | Human RCTn = 1995 | Lancet 2021, PMID 34672967 |
| Major adverse cardiovascular events | MACE-4 events were not increased on tirzepatide versus glargine (hazard ratio 0·74, 95% CI 0·51-1·08). | Human RCTn = 1995 | Lancet 2021, PMID 34672967 |
| Major adverse cardiovascular events | Hazard ratios versus controls were 0.80 (95% CI 0.57-1.11) for the four-component cardiovascular composite, 0.90 for cardiovascular death and 0.80 for all-cause death; none were statistically significant. | Meta-analysis | Nature medicine 2022, PMID 35210595 |
PubMed records for Tirzepatide and diabetes: 843 human, 48 animal (search counts, not studies we reviewed). Grades follow our evidence scale.
How strong is it?
Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Other peptides people research for diabetes
All peptides for diabetes, comparedCommon questions
Does Tirzepatide help with diabetes?
The strongest study we summarise for diabetes is human rct evidence, across 8 studies with an outcome for diabetes. A trial result is not an approval; see the legal status.
Is Tirzepatide approved for diabetes?
Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.
What is the best peptide for diabetes?
There is no single answer. Our diabetes overview compares each candidate by evidence grade and legal status rather than by popularity.
More on Tirzepatide
DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.
Sources
- 1Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
- 2Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet (London, England) · 2023PMID 37385275Accessed 2 Oct 2026
- 3Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.JAMA · 2022PMID 35133415Accessed 2 Oct 2026
- 4Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2021PMID 34186022Accessed 2 Oct 2026
- 5Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine · 2021PMID 34170647Accessed 2 Oct 2026
- 6Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.Lancet (London, England) · 2021PMID 34370970Accessed 2 Oct 2026
- 7Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.Lancet (London, England) · 2021PMID 34672967Accessed 2 Oct 2026
- 8Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.Nature medicine · 2022PMID 35210595Accessed 2 Oct 2026
Found an error? Report a correction.